Conditions: Respiratory Syncytial Virus Infection
Keywords: Immunocompromised medical conditions Respiratory Syncytial Virus Infection Infant Newborn Young children
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 28
Healthy volunteers: no

Brief summary:
To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.

Detailed description:

Arms:
arm 1: 15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.

Interventions: intervention 1: Palivizumab
Intervention descriptions: intervention 1: None

Protocol document: